Phase II clinical trial of the combination VP‐16, bleomycin, and cis‐diamminedichloroplatinum in patients with advanced upper aerodigestive squamous cell carcinoma

Publisher Website
Google Scholar
Abstract
Fifteen patients with advanced upper aerodigestive carcinomas of squamous cell histology received the three‐agent cytotoxic regimen of VP‐16, bleomycin, and cis‐diamminedichloroplatinum (CDDP) administered as a continuous 120‐h infusion. The objective response rate was 40%. Median times to progression and survival were 3.2 months and 4.3 months, respectively. Hematologic and gastrointestinal toxicities were relatively transient and manageable. Our experience indicates that this three‐drug program does not offer a substantial therapeutic advantage compared with more conventional single agent cytotoxic approaches for advanced head and neck cancer.